The incidence typically rises as your dose increases over the first 23 months of treatment, then often stabilizes or improves as your body adapts
Contraindications Janumet (sitagliptin/metformin HCl) is contraindicated in patients with: Renal disease or renal dysfunction, e.g., as suggested by serum creatinine levels 1.5 mg/dL [males], 1.4 mg/dL [females] or abnormal creatinine clearance which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia [see Warnings and Precautions]
For example, the treatment is especially dangerous for those with the extremely rare medullary thyroid cancer
That kind of analysis turns a broker from a plan administrator into a strategic advisor
10.1056/NEJMoa2113206 186
Tirzepatide compounded with glycine and B12 is a common formulation